Ionis Pharmaceuticals — Feb 19, 2025 release

The Company expects that these investments will enable Ionis to deliver accelerating value. Full Year 2025 Guidance Revenue >$600 million Operating loss on a non-GAAP basis <$495 million Cash, cash equivalents and short-term investments ~$1 . 7 billion Webcast Management will host a conference call and webcast to discuss Ionis’ fourth quarter and full year 2024 results at 11:30 a.m. Eastern time on Wednesday, February 19, 2025. Interested parties may access the webcast here . A webcast replay will be available for a limited time at the same address. To access the Company’s fourth quarter and full year 2024 earnings slides click here . For more information about SPINRAZA and QALSODY, visit https://www.spinraza.com/ and https://www.qalsody.com/ , respectively. QALSODY is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s). 4 INDICATION for TRYNGOLZA™ (olezarsen)   TRYNGOLZA™ (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).   IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is con